دورية أكاديمية
أعرض في EDS

Sickle Cell Disease and the Kidney: Filters Gone Awry.

التفاصيل البيبلوغرافية
العنوان: Sickle Cell Disease and the Kidney: Filters Gone Awry.
المؤلفون: Lebensburger JD; Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Alabama at Birmingham, 1600 7th Avenue South, Lowder 512, Birmingham, AL 35233, USA., Derebail VK; Division of Nephrology and Hypertension, Department of Medicine, University of North Carolina at Chapel Hill, UNC Kidney Center, 7024 Burnett-Womack, CB 7155, Chapel Hill, NC 27599, USA. Electronic address: vimal_derebail@med.unc.edu.
المصدر: Hematology/oncology clinics of North America [Hematol Oncol Clin North Am] 2022 Dec; Vol. 36 (6), pp. 1239-1254.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Health Science Country of Publication: United States NLM ID: 8709473 Publication Model: Print Cited Medium: Internet ISSN: 1558-1977 (Electronic) Linking ISSN: 08898588 NLM ISO Abbreviation: Hematol Oncol Clin North Am Subsets: MEDLINE
أسماء مطبوعة: Publication: <2005->: Philadelphia : Elsevier Health Science
Original Publication: Philadelphia : W.B. Saunders, c1987-
مواضيع طبية MeSH: Anemia, Sickle Cell*/complications , Anemia, Sickle Cell*/epidemiology , Anemia, Sickle Cell*/therapy , Kidney Failure, Chronic*/etiology , Acute Kidney Injury*/complications, Humans ; Kidney
مستخلص: Throughout the lifespan, the kidney of a person with sickle cell disease is at increased risk of injury to the glomeruli, tubules, and renal vasculature. This injury manifests as urine concentrating defects, enuresis, albuminuria, acute kidney injury, chronic kidney disease, and end-stage kidney disease. The outcomes for patients who progress to end-stage kidney disease are poor and access to organ transplantation is limited. Therefore, identifying risk factors for progression, intervening with renoprotective agents early in life, and improving access to care are vital for sickle cell patients.
Competing Interests: Disclosure J.D. Lebensburger has received grant finding from Pfizer and is on an advisory board for Novartis, Agios Pharmaceuticals, BPL, and Forma Therapeutics. V.K. Derebail is on an advisory board for Forma Therapeutics and Novartis, has provided consulting to Bayer and Pfizer and receives royalties from UpToDate.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
فهرسة مساهمة: Keywords: Albuminuria; Hyposthenuria; Kidney; Sickle cell
تواريخ الأحداث: Date Created: 20221118 Date Completed: 20221122 Latest Revision: 20221216
رمز التحديث: 20240628
DOI: 10.1016/j.hoc.2022.08.009
PMID: 36400541
قاعدة البيانات: MEDLINE
الوصف
تدمد:1558-1977
DOI:10.1016/j.hoc.2022.08.009